PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023
02 Agosto 2023 - 9:00AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing a growing pipeline of targeted
cancer immunotherapies and infectious disease vaccines based on the
Company’s proprietary T cell activating platforms, today announced
that Dr. Frank Bedu-Addo, Chief Executive Officer, will participate
in a fireside chat at the BTIG Virtual Biotechnology Conference
2023 being held August 7-8, 2023. Details for the event are as
follows:
BTIG Virtual Biotechnology Conference
2023Presentation Date: Tuesday, August 8, 2023Event:
Fireside chat Time: 11:30 AM EDT
For more information about the conference or to
schedule one-on-one meetings, please contact your BTIG
representative directly.
About PDS BiotechnologyPDS
Biotech is a clinical-stage immunotherapy company developing a
growing pipeline of targeted cancer and infectious disease
immunotherapies based on our proprietary Versamune®, Versamune®
plus PDS0301, and Infectimune® T cell-activating platforms. We
believe our targeted immunotherapies have the potential to overcome
the limitations of current immunotherapy approaches through the
activation of the right type, quantity and potency of T cells. To
date, our lead Versamune® clinical candidate, PDS0101, has
demonstrated the ability to reduce and shrink tumors and stabilize
disease in combination with approved and investigational
therapeutics in patients with a broad range of HPV16-associated
cancers in multiple Phase 2 clinical trials and will be advancing
into a Phase 3 clinical trial in combination with KEYTRUDA® for the
treatment of recurrent/metastatic HPV16-positive head and neck
cancer in 2023. Our Infectimune® based vaccines have also
demonstrated the potential to induce not only robust and durable
neutralizing antibody responses, but also powerful T cell
responses, including long-lasting memory T cell responses in
pre-clinical studies to date. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Investor Relations:Deanne
RandolphPDS BiotechPhone: +1 (908) 517-3613Email:
drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404)
736-3838Email: pdsb@cg.capital
Media Contacts:Tiberend
Strategic Advisors, Inc.Dave SchemeliaPhone: +1 (609)
468-9325dschemelia@tiberend.com
Eric ReissPhone: +1 (802)
249-1136ereiss@tiberend.com
PDS Biotechnology (NASDAQ:PDSB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
PDS Biotechnology (NASDAQ:PDSB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024